Stock Price

The toy giant's new $400M debt offering isn't just about paying bills; it's a strategic move to extend its financial runway and invest in its future.

AI firm YXT.com lands on a top innovation list with tech giants, but can its cutting-edge training solutions navigate a complex market and redefine work?

Ad-tech giant Teads reports massive revenue growth post-merger, but a $352M impairment and restructuring signal deep integration challenges.

German defense tech firm RENK Group reports a record €1.37B revenue, fueled by a 24% surge in its defense business amid global geopolitical tensions.

The VCT posts flat returns but rewards investors with a special dividend, announcing a new chair as it navigates a shifting regulatory landscape.

Once a failing firm, Aurelion Inc. bet its future on tokenized gold. The gamble paid off with a profitable quarter, but regulatory risks loom large.

Hain Celestial completes sale of Terra and Garden of Eatin' to pay down debt, betting its future on the high-margin tea, yogurt, and baby food markets.

Facing delisting for being a 'public shell,' XTL Biopharma plans an appeal while its new acquisition and valuable IP hang in the balance.

Post-acute leader PACS Group reports a landmark year with a 29% revenue jump, fueled by superior patient care metrics and a disciplined expansion strategy.

Zoomcar's latest financing move involves complex warrants, raising questions about shareholder dilution and its strategy in India's car-sharing race.

Perrigo takes a massive $1.3B impairment charge and plans a 7% workforce reduction as it pivots to a 'CORE' business amid a challenging outlook.

Titan International beat expectations in Q4, driven by a 21% surge in its construction division, and now eyes a strong 2026 as OEM destocking ends.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

Toymaker JAKKS Pacific launches an ambitious new platform targeting the multi-billion dollar anime, manga, and creator markets. Can it beat the competition?

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

RCI faces a Nasdaq deadline amid late financial reports linked to a NY indictment. Can strong profits and a new CEO team navigate the regulatory storm?

Electra Battery Materials boosts its financing to $25M, accelerating its push to commission North America's only cobalt refinery for the EV market.

First Horizon's financial and credit chiefs will present at a key conference. We dive into their strategy amid industry headwinds and strong 2025 results.